Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patent Reform Bill Would Allow Confirmatory Use Of Gene Tests Under Manager's Amendment

This article was originally published in The Pink Sheet Daily

Executive Summary

More than 30 amendments have been proposed to the bill in the House, including those to strike the conversion to a "first-to-file" patent system and eliminate PTO's fee-setting authority.

You may also be interested in...

House Patent Reform Bill Hits Roadblock As Appropriations Cmte. Objects To PTO Fee Provision

Stakeholders are furiously lobbying representatives to get them to retain a provision that would end PTO fee diversion to other government programs.

Myriad's BRCA Gene Patents Struck Down In Court; Are Biotech's Foundations Shaking?

Judge finds that isolated DNA is not different from that in the body and thus unpatentable; Myriad says its products are covered by other patents.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts